Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (571-580 of 652) with videos related to

Pageof 66
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple MyelomaAntonio Palumbo, Francesca Gay, Federica Cavallo, et al.
European Journal of Haematology|May 16, 2017
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysisPhilippe Moreau, Meletios A Dimopoulos, Paul G Richardson, et al.
Haematologica|February 6, 2014
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myelomaMonika Engelhardt, Evangelos Terpos, Martina Kleber, et al.
The Lancet. Oncology|February 15, 2014
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient dataAntonio Palumbo, Sara Bringhen, Shaji K Kumar, et al.
The New England Journal of Medicine|October 6, 2016
Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
Journal of Hematology|November 4, 2024
Siltuximab in Idiopathic Multicentric Castleman Disease: Real-World ExperienceCiprian Jitaru, Argyris Symeonidis, Sorina Badelita, et al.
Haematologica|January 15, 2026
Hepatic response criteria in light chain amyloidosis: a multicenter validation studyEli Muchtar, Giovanni Palladini, Stefan Schonland, et al.
Blood|August 16, 2011
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)Antonio Palumbo, Sara Bringhen, Heinz Ludwig, et al.
Haematologica|August 8, 2015
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasoneMeletios A Dimopoulos, Katja C Weisel, Kevin W Song, et al.
Lancet (London, England)|December 15, 2018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trialMeletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, et al.
Pageof 66

Showing results (571-580 of 652) with videos related to

Sort By:
Pageof 66
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple MyelomaAntonio Palumbo, Francesca Gay, Federica Cavallo, et al.
European Journal of Haematology|May 16, 2017
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysisPhilippe Moreau, Meletios A Dimopoulos, Paul G Richardson, et al.
Haematologica|February 6, 2014
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myelomaMonika Engelhardt, Evangelos Terpos, Martina Kleber, et al.
The Lancet. Oncology|February 15, 2014
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient dataAntonio Palumbo, Sara Bringhen, Shaji K Kumar, et al.
The New England Journal of Medicine|October 6, 2016
Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
Journal of Hematology|November 4, 2024
Siltuximab in Idiopathic Multicentric Castleman Disease: Real-World ExperienceCiprian Jitaru, Argyris Symeonidis, Sorina Badelita, et al.
Haematologica|January 15, 2026
Hepatic response criteria in light chain amyloidosis: a multicenter validation studyEli Muchtar, Giovanni Palladini, Stefan Schonland, et al.
Blood|August 16, 2011
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)Antonio Palumbo, Sara Bringhen, Heinz Ludwig, et al.
Haematologica|August 8, 2015
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasoneMeletios A Dimopoulos, Katja C Weisel, Kevin W Song, et al.
Lancet (London, England)|December 15, 2018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trialMeletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, et al.
Pageof 66